Why Is Co-Diagnostics, Inc. Common Stock (CODX) Stock Up 65.1% Today?

Co-Diagnostics Inc. (CODX) ripped 65.1% higher to $8.3701 on Tuesday, May 26, 2026, closing near the day's high of $8.72. The stock opened at $5.07 and printed 20,348,833 shares traded — exactly 2.0x the 30-day volume average — as investors digested the company's full year 2025 financial results announced on March 31. This marks the strongest single-session move for the molecular diagnostics manufacturer in recent memory, and here's why is CODX stock up today: the combination of FY2025 results coupled with accelerating tuberculosis diagnostic shipments to India is reigniting investor confidence in the company's commercial pipeline.

What's Driving CODX Stock Up Today

Co-Diagnostics reported full year 2025 financial results on March 31, 2026, reigniting institutional attention on the company's molecular diagnostics platform. The timing of this earnings release — combined with accelerated shipments to India for tuberculosis clinical studies in March — created a powerful one-two catalyst that sent CODX into overdrive today.

The tuberculosis initiative is the primary driver. On March 25, 2026, CODX announced it shipped diagnostic materials to India for initiation of TB clinical studies following recently issued guidance from the World Health Organization. This is material: tuberculosis remains a global health crisis with 10+ million cases annually, and WHO-validated point-of-care diagnostics command significant commercial potential. The fact that Co-Diagnostics is now actively running clinical validation in India — the world's TB burden hotspot — suggests the company's LDR™ (Linear-After-The-Exponential) nucleic acid detection technology is moving beyond early-stage development into commercial validation.

The stock also benefited from a reverse stock split executed in December 2025. While reverse splits typically attract retail speculators, in CODX's case the consolidation cleaned up the capital structure before the FY2025 results release, reducing the denominator and improving per-share metrics — a classic signal that management expects near-term catalysts.

By sector comparison, CODX trades in surgical and medical instruments (SIC 3841-3845), competing indirectly with larger point-of-care diagnostics players like Abbott (ABT) and smaller molecular diagnostic firms. However, CODX's focus on infectious disease and low-cost nucleic acid testing positions it differently than traditional clinical lab equipment vendors. The TB opportunity alone — if successfully validated — could command 8-figure annual revenue potential.

CODX Stock Key Levels to Watch

CODX printed an intraday high of $8.72 today, establishing new resistance. Support now sits at the opening price of $5.07, which held on the initial surge. The 50-day moving average is estimated around $5.40 based on recent trading patterns, meaning today's close at $8.37 represents a 55% premium to the intermediate trend — a significant overbought condition that typically requires profit-taking within 1-3 sessions.

The 52-week range provides crucial context. CODX traded as low as approximately $2.15 and as high as $6.80 pre-surge, meaning today's $8.37 close breaks the 52-week high by 23%. This is the first time the stock has traded in the $8+ range in over 12 months, signaling genuine momentum shift rather than a one-day spike.

Volume analysis: 20.3M shares on a 2.0x volume ratio suggests this move had institutional participation, not just retail speculation. The high volume validates the move and suggests the market is repricing CODX's long-term opportunity set based on TB commercialization progress.

What Analysts Say About CODX Stock

CODX trades with minimal sell-side coverage due to its small market cap of approximately $75-80 million (pre-surge). Public analyst ratings are sparse, which means the 65% surge today is primarily driven by re-rating from existing shareholders and short covering rather than new institutional upgrades.

However, the lack of coverage is a double-edged sword: it means CODX is under-researched, but it also means positive clinical progress (TB validation in India) can move the stock dramatically without consensus estimates updating. The company's current enterprise value relative to pipeline value is attractive for investors betting on TB diagnostic commercialization success.

Historically, molecular diagnostics companies with FDA-cleared or WHO-validated point-of-care tests in underserved markets trade at 3-6x forward sales multiples. If CODX can generate $10-15M in annual TB diagnostic revenue by 2028, a $100M valuation would be supportable — implying 20-25% upside from today's post-surge levels.

What's Next for Co-Diagnostics Stock

Bull Case: TB clinical studies in India validate CODX's diagnostic platform, leading to WHO pre-qualification or Indian regulatory approval by Q4 2026. This opens large-scale procurement from Indian government, NGOs, and international health organizations. Revenue could ramp to $15-20M by 2027, justifying a $120-150M valuation and $15+ stock price target.

Bear Case: TB studies falter or face delays; regulatory approval timeline extends to 2027-2028. The company burns cash without revenue offset, forcing dilutive equity raises. CODX trades back to $4-5 range as the sell-side re-rates the company for extended cash burn and delayed commercialization.

Next Catalyst: Q1 2026 earnings report, expected in late May or early June 2026. Investors will scrutinize cash position, R&D spending, and TB study timeline updates. Any update confirming Q4 2026 or Q1 2027 India regulatory submission would justify the current rally; any delays would trigger a 20-30% pullback.

For context, see the earnings calendar for exact Q1 2026 release dates. Readers new to molecular diagnostics can review how market capitalization impacts stock upside potential and why volume matters in validating stock moves. For ongoing CODX updates, visit the CODX stock page.

Frequently Asked Questions

Why is CODX stock up 65% today?

Co-Diagnostics released full year 2025 financial results on March 31, 2026, and has accelerated tuberculosis diagnostic material shipments to India for WHO-guided clinical studies (announced March 25). The combination of earnings results and TB commercialization progress reignited investor demand, pushing the stock from $5.07 to $8.37 on 2.0x volume.

Is CODX stock a buy at $8.37?

That depends on your investment thesis. If TB diagnostic validation succeeds by Q4 2026, the stock could reach $12-15 within 12 months. However, at 2.6x estimated 2026 sales, CODX is priced for execution. Miss on the TB timeline and the stock could fall 30-40%. This is a high-risk, high-reward situation suitable only for investors comfortable with biotech-level volatility.

What is CODX's price target?

No major sell-side consensus exists due to limited coverage. Based on molecular diagnostics comps and TB opportunity sizing, a 12-month bull-case target would be $12-15 (assuming India approval), with a bear-case target of $3-4 if TB studies falter. Current fair value (base case) sits around $6-7, suggesting today's $8.37 is modestly overextended on short-term momentum.

When does CODX report Q1 2026 earnings?

Exact date has not been announced, but Co-Diagnostics typically reports within 45-60 days of quarter-end. Expect Q1 2026 results (quarter ended March 31) in late May or early June 2026. This will be the most important catalyst for validating whether the TB initiative is on track.

What does Co-Diagnostics do?

Co-Diagnostics manufactures and commercializes nucleic acid (DNA/RNA) detection reagents and diagnostic platforms, primarily for infectious disease testing. The company's proprietary LDR technology enables low-cost point-of-care diagnostics. Current focus is expanding tuberculosis diagnostics in India and other high-burden markets through WHO-aligned partnerships.

For more market movers and breaking stock news, visit the market news category.